Charlotte de Jonge
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Charlotte de Jonge has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Jan Willem M. Greve
Department of General Surgery, Atrium Medical Center Parkstad, Heerlen, the Netherlands
3 shared publications - Nicole D. Bouvy
Department of Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands
2 shared publications - Sander S. Rensen
Department of Surgery, NUTRIM School of Nutrition and Translational Research in Metabolism Maastricht University Maastricht The Netherlands
2 shared publications - Wim A. Buurman
Department of Psychiatry and Neuropsychology, Faculty of Health, Medicine and Life Sciences, Maastricht University, P.O. Box 616, 6200 MD, Maastricht, The Netherlands
2 shared publications - Bark Betzel
Department of General Surgery, Rijnstate Medical Center, Arnhem, The Netherlands
1 shared publication - Carel Wynand le Roux
University College Dublin, Dublin, Ireland
1 shared publication
Latest Publications
- Open Access
- 6 November 2017
- Published by Springer Nature in Obesity Surgery
- Vol. 28 (5) , 1255-1262
The Effect of 6 and 12 months Duodenal-Jejunal Bypass Liner Treatment on Obesity and Type 2 Diabetes: a Crossover Cohort Study
The aim of this research was to study the duodenal-jejunal bypass liner (DJBL) treatment for obesity and type 2 diabetes mellitus (T2DM) in patients after dietary treatment in a cross-over design.
- 6 November 2017
- Published by Springer Nature in Obesity Surgery
- Vol. 28 (5) , 1255-1262
Open AccessThe Effect of 6 and 12 months Duodenal-Jejunal Bypass Liner Treatment on Obesity and Type 2 Diabetes: a Crossover Cohort Study
The aim of this research was to study the duodenal-jejunal bypass liner (DJBL) treatment for obesity and type 2 diabetes mellitus (T2DM) in patients after dietary treatment in a cross-over design.
- 7 October 2015
- Published by Springer Nature in Obesity Surgery
- Vol. 26 (3) , 672-678
Impact of Duodenal-Jejunal Exclusion on Satiety Hormones
Bariatric procedures that exclude the proximal small intestine lead to significant weight loss which is probably mediated by changes in hormones that alter appetite, such as peptide YY (PYY), ghrelin, cholecystokinin (CCK), and leptin. Here, the effect of the non-surgical duodenal-jejunal bypass liner (DJBL) on concentrations of hormones implicated in appetite control was investigated.
- 7 October 2015
- Published by Springer Nature in Obesity Surgery
- Vol. 26 (3) , 672-678
Impact of Duodenal-Jejunal Exclusion on Satiety Hormones
Bariatric procedures that exclude the proximal small intestine lead to significant weight loss which is probably mediated by changes in hormones that alter appetite, such as peptide YY (PYY), ghrelin, cholecystokinin (CCK), and leptin. Here, the effect of the non-surgical duodenal-jejunal bypass liner (DJBL) on concentrations of hormones implicated in appetite control was investigated.
- 20 December 2013
- Published by Springer Nature in Obesity Surgery
- Vol. 24 (2) , 337-341
Six Months of Treatment with the Endoscopic Duodenal-Jejunal Bypass Liner Does Not Lead to Decreased Systemic Inflammation in Obese Patients with Type 2 Diabetes
- 20 December 2013
- Published by Springer Nature in Obesity Surgery
- Vol. 24 (2) , 337-341
Six Months of Treatment with the Endoscopic Duodenal-Jejunal Bypass Liner Does Not Lead to Decreased Systemic Inflammation in Obese Patients with Type 2 Diabetes
- 1 January 2012
- Vol. 156 (23) , A4630
[Practice guideline for the treatment of morbid obesity].
The increasing prevalence of obesity and its related comorbidities represents an increasing burden for the Dutch health care and requires effective therapy. The primary treatment of obesity consists of lifestyle interventions directed at lifestyle change; in morbidly obese subjects only bariatric surgery is cost-effective in the long term, with respect to both weight loss and reduction in comorbidity. There is a new Dutch multidisciplinary practice guideline on the treatment of morbid obesity, in which the following aspects are covered: indications for surgery, pre-operative policy advice, considerations for the type of operation, and the short and long term follow-up after bariatric surgery. Patients between 18 and 65 years old are eligible for bariatric surgery if they have a BMI ≥ 40 kg/m2 or a BMI ≥ 35 kg/m2 in the presence of comorbidity. In adolescents under 18 bariatric surgery should only be performed in a research setting; in patients older than 65 years bariatric surgery can be performed exceptionally, preferably in a centre with large experience.
- 1 January 2012
- Vol. 156 (23) , A4630
[Practice guideline for the treatment of morbid obesity].
The increasing prevalence of obesity and its related comorbidities represents an increasing burden for the Dutch health care and requires effective therapy. The primary treatment of obesity consists of lifestyle interventions directed at lifestyle change; in morbidly obese subjects only bariatric surgery is cost-effective in the long term, with respect to both weight loss and reduction in comorbidity. There is a new Dutch multidisciplinary practice guideline on the treatment of morbid obesity, in which the following aspects are covered: indications for surgery, pre-operative policy advice, considerations for the type of operation, and the short and long term follow-up after bariatric surgery. Patients between 18 and 65 years old are eligible for bariatric surgery if they have a BMI ≥ 40 kg/m2 or a BMI ≥ 35 kg/m2 in the presence of comorbidity. In adolescents under 18 bariatric surgery should only be performed in a research setting; in patients older than 65 years bariatric surgery can be performed exceptionally, preferably in a centre with large experience.